Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections.

[1]  F. Pea,et al.  Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. , 2012, The Journal of antimicrobial chemotherapy.

[2]  K. Gould,et al.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections , 2012, Infection and drug resistance.

[3]  Kana Matsumoto,et al.  Correlation between serum linezolid concentration and the development of thrombocytopenia , 2012, Scandinavian journal of infectious diseases.

[4]  N. Ford,et al.  Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  J. Xing,et al.  Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. , 2011, International journal of antimicrobial agents.

[6]  S. Higuchi,et al.  Population Pharmacokinetic and Pharmacodynamic Analysis of Linezolid and a Hematologic Side Effect, Thrombocytopenia, in Japanese Patients , 2011, Antimicrobial Agents and Chemotherapy.

[7]  H. Derendorf,et al.  Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin , 2010, European journal of medical research.

[8]  P. Viale,et al.  Therapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric Analysis , 2010, Antimicrobial Agents and Chemotherapy.

[9]  Kazuaki Matsumoto,et al.  Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. , 2010, International journal of antimicrobial agents.

[10]  E. Clementi,et al.  Determination of Linezolid in Human Plasma by High-Performance Liquid Chromatography With Ultraviolet Detection , 2010, Therapeutic drug monitoring.

[11]  R. Danesi,et al.  Pharmacological Issues of Linezolid , 2010, Clinical pharmacokinetics.

[12]  W. Haefeli,et al.  Pharmacokinetics of linezolid in septic patients with and without extended dialysis , 2010, European Journal of Clinical Pharmacology.

[13]  Y. Tsuji,et al.  Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure , 2008, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[14]  C. Kloft,et al.  Does Linezolid Inhibit Its Own Metabolism?—Population Pharmacokinetics As a Tool to Explain the Observed Nonlinearity in Both Healthy Volunteers and Septic Patients , 2007, Drug Metabolism and Disposition.

[15]  G. French.  Safety and tolerability of linezolid. , 2003, The Journal of antimicrobial chemotherapy.